Dr. Shen received his PhD in Genetics Genomics and Master of Public Health in Public Health Policy and Management from the University of Florida (2018). Subsequently, he conducted postdoctoral research in Human Genetics at Harvard Medical School and the Broad Institute of MIT and Harvard. His research primarily focuses on utilizing genome editing techniques to investigate the regulatory mechanisms of hemoglobin gene expression in red blood cells and pioneering gene therapy approaches for severe genetic anemias, such as sickle cell disease and thalassemia. Dr. Shen has authored research papers and reviews in prominent journals spanning human genetics, molecular genetics, and molecular therapy, including Nature Communications, Molecular and Cellular Biology, PLOS Genetics, and Molecular Therapy - Nucleic Acid. In addition to his academic pursuits, Dr. Shen possesses extensive experience in innovation and entrepreneurship. He is dedicated to translating cutting-edge biomedical innovations into practical solutions for some of the most challenging human health issues, including genetic diseases, cancer, and aging.

Epigenetic reprogramming interventions and gene therapy for aging reversal

Engineering of AAV gene therapy delivery vector

Establishment of epigenome editing system for gene expression modulation